Coherus BioSciences Q3 2023 Adj EPS $(0.27) Beats $(0.31) Estimate, Sales $74.57M Miss $83.56M Estimate
Portfolio Pulse from totan@benzinga.com
Coherus BioSciences reported Q3 2023 adjusted EPS of $(0.27), beating the estimate of $(0.31) by 12.9%. However, the company's sales of $74.57M missed the estimate of $83.56M by 10.76%. Despite the miss, this represents a 64.16% increase in sales compared to the same period last year.
November 06, 2023 | 9:40 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Coherus BioSciences reported better than expected Q3 2023 EPS but missed on sales. Despite the miss, sales are up 64.16% YoY.
Coherus BioSciences reported a better than expected EPS, which is a positive signal for investors. However, the company missed on sales, which could be a concern. Despite the miss, the YoY increase in sales is a positive sign, indicating growth. Therefore, the impact on the stock price could be neutral in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100